Molecular Partners AG (MOLN.SW)
CHF 4.83
(4.43%)
CHF 4.83
(4.43%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 20.3 Million CHF | -9.89% |
| 2022 | 72.94 Million CHF | 0.27% |
| 2021 | 72.74 Million CHF | 7.51% |
| 2020 | 67.67 Million CHF | 18.63% |
| 2019 | 57.04 Million CHF | 19.42% |
| 2018 | 47.76 Million CHF | 4.15% |
| 2017 | 45.86 Million CHF | 7.84% |
| 2016 | 42.52 Million CHF | 35.7% |
| 2015 | 31.33 Million CHF | 26.44% |
| 2014 | 24.78 Million CHF | -2.04% |
| 2013 | 25.3 Million CHF | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 17.99 Million CHF | 5.35% |
| 2024 Q3 | 15.27 Million CHF | -9.77% |
| 2024 Q2 | 16.92 Million CHF | -5.93% |
| 2023 Q2 | 16.29 Million CHF | -10.14% |
| 2023 Q1 | 18.13 Million CHF | 2.78% |
| 2023 Q4 | 17.07 Million CHF | 6.54% |
| 2023 Q3 | 16.03 Million CHF | -1.64% |
| 2023 FY | 65.72 Million CHF | -9.89% |
| 2022 Q3 | 17.02 Million CHF | -5.61% |
| 2022 Q1 | 20.22 Million CHF | 15.14% |
| 2022 FY | 72.94 Million CHF | 0.27% |
| 2022 Q4 | 17.64 Million CHF | 3.63% |
| 2022 Q2 | 18.04 Million CHF | -10.79% |
| 2021 Q1 | 19.34 Million CHF | -10.47% |
| 2021 Q2 | 19.47 Million CHF | 0.68% |
| 2021 FY | 72.74 Million CHF | 7.51% |
| 2021 Q4 | 17.56 Million CHF | 7.33% |
| 2021 Q3 | 16.36 Million CHF | -15.98% |
| 2020 Q2 | 3.42 Million CHF | -14.41% |
| 2020 Q3 | 15.45 Million CHF | 350.82% |
| 2020 FY | 67.67 Million CHF | 18.63% |
| 2020 Q1 | 4 Million CHF | 20.85% |
| 2020 Q4 | 21.6 Million CHF | 39.82% |
| 2019 Q2 | 4.01 Million CHF | 0.0% |
| 2019 FY | 57.04 Million CHF | 19.42% |
| 2019 Q4 | 3.31 Million CHF | 0.0% |
| 2019 Q3 | 3.31 Million CHF | -17.52% |
| 2019 Q1 | 4.01 Million CHF | 32.13% |
| 2018 Q4 | 3.04 Million CHF | 0.0% |
| 2018 FY | 47.76 Million CHF | 4.15% |
| 2018 Q1 | 1.89 Million CHF | 108.28% |
| 2018 Q2 | 1.89 Million CHF | 0.0% |
| 2018 Q3 | 3.04 Million CHF | 60.09% |
| 2017 Q3 | 911.99 Thousand CHF | -77.16% |
| 2017 FY | 45.86 Million CHF | 7.84% |
| 2017 Q4 | 911.99 Thousand CHF | 0.0% |
| 2017 Q2 | 3.99 Million CHF | 47.89% |
| 2017 Q1 | 2.69 Million CHF | 454.41% |
| 2016 Q3 | 1.59 Million CHF | -9.04% |
| 2016 Q4 | 487 Thousand CHF | -69.56% |
| 2016 FY | 42.52 Million CHF | 35.7% |
| 2016 Q1 | 3.5 Million CHF | 439.29% |
| 2016 Q2 | 1.75 Million CHF | -49.74% |
| 2015 Q3 | 1.54 Million CHF | -86.16% |
| 2015 Q2 | 11.19 Million CHF | 210.93% |
| 2015 FY | 31.33 Million CHF | 26.44% |
| 2015 Q1 | 3.59 Million CHF | -82.11% |
| 2015 Q4 | 649 Thousand CHF | -58.1% |
| 2014 Q4 | 20.12 Million CHF | 1886.07% |
| 2014 Q3 | 1.01 Million CHF | -76.74% |
| 2014 Q2 | 4.35 Million CHF | 0.0% |
| 2014 Q1 | 4.35 Million CHF | 6061.01% |
| 2014 FY | 24.78 Million CHF | -2.04% |
| 2013 Q2 | 24.16 Thousand CHF | 0.0% |
| 2013 FY | 25.3 Million CHF | 0.0% |
| 2013 Q1 | 24.16 Thousand CHF | 0.0% |
| 2013 Q4 | 70.7 Thousand CHF | 192.57% |
| 2013 Q3 | 24.16 Thousand CHF | 0.0% |
| 2012 Q4 | 24.16 Thousand CHF | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Addex Therapeutics Ltd | 11.89 Million CHF | -70.687% |
| BB Biotech AG | -199.56 Million CHF | 110.173% |
| Basilea Pharmaceutica AG | 111.63 Million CHF | 81.814% |
| Evolva Holding SA | 89.66 Million CHF | 77.357% |
| Idorsia Ltd | 400.38 Million CHF | 94.929% |
| Kuros Biosciences AG | 36.21 Million CHF | 43.947% |
| Relief Therapeutics Holding AG | 114.94 Million CHF | 82.337% |
| Santhera Pharmaceuticals Holding AG | 31.33 Million CHF | 35.21% |